Oral diseases are among the most
common encountered health issues
worldwide, which are usually associated with anomalies of the oral
cavity, jaws, and salivary glands. Despite the availability of numerous
treatment modalities for oral disorders, a limited clinical response
has been observed because of the inefficacy of the drugs and countless
adverse side effects. Therefore, the development of safe, efficacious,
and wide-spectrum therapeutics is imperative in the battle against
oral diseases. Curcumin, extracted from the golden spice turmeric,
is a well-known natural polyphenol that has been extensively studied
for its broad pleiotropic attributes and its ability to modulate multiple
biological processes. It is well-documented to target pro-inflammatory
mediators like NF-κB, ROS, COX-2, IL-1, IL-2, TGF-β, growth
factors, apoptotic proteins, receptors, and various kinases. These
properties make curcumin a promising nutraceutical in the treatment
of many oral diseases like oral submucous fibrosis, oral mucositis,
oral leukoplakia, oral erythroplakia, oral candidiasis, aphthous stomatitis,
oral lichen planus, dental caries, periodontitis, and gingivitis.
Numerous in vitro and in vivo studies
have shown that curcumin alleviates the symptoms of most of the oral
complications, including the inhibition of the progression of oral
cancer. In this regard, many clinical trials have been completed,
and many are ongoing to investigate the “curcumin effect”
in oral maladies. Therefore, the current review delineates the mechanistic
framework of curcumin’s propensity in curbing oral diseases
and present outcomes of the clinical trials of curcumin-based therapeutics
that can provide a breakthrough in the clinical management of these
diseases.